This work is licensed under a Creative Commons Attribution 4.0 International License.
Lavracin
General Information
DRACP ID DRACP00771
Peptide Name Lavracin
Sequence WDPYFAGVKKLTKAILAVRA
Sequence Length 20
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| MEC-7 | Invasive breast carcinoma of no special type | Carcinoma | EC50=(50-100)µM | MTT assay | 72h | 1 |
| MEC-7 | Invasive breast carcinoma of no special type | Carcinoma | Not active up to 100 µM | MTT assay | 72h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HDME: Not active up to 100 µM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antibacterial
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Amidation
Other Modification None
Chiral L
Physicochemical Information
Formula C108H171N27O25
Absent amino acids CEHMNQS
Common amino acids A
Mass 258681
Pl 10.64
Basic residues 4
Acidic residues 1
Hydrophobic residues 11
Net charge 3
Boman Index -667
Hydrophobicity 29.5
Aliphatic Index 107.5
Half Life
Mammalian: 1 hour
Yeast: 2 min
E.coli: 2 min
Extinction Coefficient cystines 6990
Absorbance 280nm 367.89
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 28799716
Title Rational Design of Membrane-Pore-Forming Peptides.
Year 2017
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.